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The Journal of Immunology
Identification of Immune Effectors Essential to the Control of
Primary and Secondary Intranasal Infection with Brucella
melitensis in Mice
Delphine Hanot Mambres,*,1 Arnaud Machelart,*,1 Georges Potemberg,*
Carl De Trez,† Bernhard Ryffel,‡,x Jean-Jacques Letesson,* and Eric Muraille*,{
The mucosal immune system represents the first line of defense against Brucella infection in nature. We used genetically deficient
mice to identify the lymphocytes and signaling pathways implicated in the control of primary and secondary intranasal infection
with B. melitensis. Our analysis of primary infection demonstrated that the effectors implicated differ at the early and late stages
and are dependent on the organ. TCR-d, TAP1, and IL-17RA deficiency specifically affects early control of Brucella in the lungs,
whereas MHC class II (MHCII) and IFN-gR deficiency impairs late control in the lungs, spleen, and liver. Interestingly, IL-
12p352/2 mice display enhanced Brucella growth in the spleen but not in the lungs or liver. Secondary intranasal infections are
efficiently contained in the lung. In contrast to an i.p. infectious model, in which IL-12p35, MHCII, and B cells are strictly
required for the control of secondary infection, we observed that only TCR-b deficiency or simultaneous neutralization of IL-
12p35– and IL-17A–dependent pathways impairs the memory protective response against a secondary intranasal infection.
Protection is not affected by TCR-d, MHCII, TAP1, B cell, IL-17RA, or IL-12p35 deficiency, suggesting that CD4+ and CD8+
a/b+ T cells are sufficient to mount a protective immune response and that an IL-17A–mediated response can compensate for the
partial deficiency of an IFN-g–mediated response to control a Brucella challenge. These findings demonstrate that the nature of
the protective memory response depends closely on the route of infection and highlights the role of IFN-g–and IL-17RA–mediated
responses in the control of mucosal infection by Brucella. The Journal of Immunology, 2016, 196: 3780–3793.
B
rucella (alpha-proteobacteria) are facultative intracellu-
lar Gram-negative coccobacilli that infect mammals and
cause brucellosis. Human brucellosis is a zoonotic in-
fection transmitted through ingestion, inhalation, or contact of
contaminated animal products with the conjunctiva or skin lesions
(1). Brucella display strong tissue tropism for the reticuloendo-
thelial and reproductive systems, with a stealthy intracellular
lifestyle that limits exposure to protective immune responses
(reviewed in Ref. 2). The furtive nature of Brucella is attributed, in
large part, to the weak agonist activity of its LPS and active
suppression of the innate immune response by immunoregulatory
factors such as TIR-containing proteins that inhibit MyD88 sig-
naling pathways. Although rarely fatal, Brucella can cause a
devastating multiorgan disease in humans with serious health
complications in the absence of prolonged antibiotic treatment (3).
Despite significant progress, the incidence of human brucellosis
remains very high in endemic areas (4) and is considered to be
largely underestimated (5). In addition, Brucella species have
been weaponized by several governments and are classified as
category B threat agents (6). Because complete eradication of
Brucella is unpractical because of its presence in a wide range of
wild mammals (7, 8), antibiotic treatment is costly, and patients
frequently suffer from resurgence of the bacteria (9), vaccination
remains the most rational strategy to confer durable protection on
populations living in endemic countries and professionals who
are frequently exposed to Brucella. Unfortunately, there is no
available human brucellosis vaccine; all commercially available
animal vaccines are live vaccines that would cause disease in
humans (10, 11).
The first step in the rational selection of candidate vaccines is to
identify immune markers associated with protective immunity.
The central role played by the MyD88/IL-12 signaling axis
(12–14), IFN-g–producing CD4+ T cells (15–17), and specific Abs
(17) in the protective immune response against Brucella has been
well established. However, those results were obtained primarily
through analysis of the splenic immune response following i.p.
infection, and they teach us little about mucosal immune defenses
constituting the first barrier protecting the host against brucellosis
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under natural conditions. Human brucellosis is frequently ac-
quired via aerosol exposure (18), and 10–100 bacteria seem suf-
ficient to infect humans in this manner (19). Aerosol or intranasal
(i.n.) exposure of mice (20) or macaques (21) to low (102–103)
doses of virulent B. melitensis 16M caused chronic pulmonary
infection, followed by systemic infection of the spleen and liver.
Interestingly, the TLRs involved in the control of Brucella fol-
lowing i.n. infection in mice appear different in the lungs, liver,
and spleen (22), suggesting that the nature of the protective im-
mune response may depend on the organ. Therefore, caution is
warranted when interpreting the significance of host immune ef-
fector components identified previously only via analysis of the
spleen.
In the current study, we analyzed the protection levels and
immune responses elicited in several compartments (lungs, spleen,
liver, and blood) at different times after primary and secondary i.n.
infection of C57BL/6 mice with virulent B. melitensis 16M. We
used a large panel of genetically deficient mice to compare the
importance of the IFN-g–mediated response, the IL-17RA–me-
diated response, and g/d+ T, a/b+ T, CD4+ T, CD8+ T, and B cells
in the control of primary and secondary Brucella infection.
Materials and Methods
Ethics statement
The procedures used in this study and the handling of the mice complied
with current European legislation (directive 86/609/EEC) and the corre-
sponding Belgian law “Arrêté royal relatif à la protection des animaux
d’expérience du 6 avril 2010 publié le 14 mai 2010.” The Animal Welfare
Committee of the Université de Namur (Namur, Belgium) reviewed and
approved the complete protocol (Permit Number 05-558).
Mice and reagents
Wild-type (wt) C57BL/6 mice were acquired from Harlan (Bicester, U.K.).
IFNgR2/2 C57BL/6 mice (23), IL-12p352/2 C57BL/6 mice (24), and
IL12p402/2 C57BL/6 mice (25) were acquired from Dr. B. Ryffel (Uni-
versity of Orleans). IL17RA2/2 C57BL/6 mice (26) and IL23p192/2
C57BL/6 mice (27) were acquired from Dr. K. Huygen (Belgian Scientific
Institute for Public Health, Bruxelles, Belgium). TAP12/2 C57BL/6 mice
(28) and MHCII2/2 C57BL/6 mice (29) were acquired from Jörg Reimann
(University of Ulm, Ulm, Germany). RAG12/2 C57BL/6 mice (30) were
acquired from Dr. S. Goriely (Université Libre de Bruxelles). AID2/2
C57BL/6 mice (31) were acquired from Dr. H. Jacobs (Netherlands
Cancer Institute, Amsterdam, the Netherlands). TNF-a2/2 C57BL/6 (32)
and IL-62/2 C57BL/6 mice (33) were acquired from Dr. C. De Trez
(Vrije Universiteit Brussel). CD3ε2/2, TCR-b2/2, TCR-d2/2, IL-1R2/2,
CCR22/2, and MuMT2/2 C57BL/6 mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). All wt and deficient mice used in
this study were bred in the animal facility of the Gosselies campus of the
Université Libre de Bruxelles.
We used a wt strain of Brucella melitensis 16M and a strain stably
expressing a rapidly maturing variant of the red fluorescent protein DsRed
(34), the mCherry protein (mCherry-expressing Brucella melitensis
[mCherry-Br]), under the control of the strong Brucella spp. promoter,
PsojA. Construction of the mCherry-Br strain was described in detail (35).
It was grown in biosafety level III laboratory facilities. Cultures were grown
overnight with shaking at 37˚C in 2YT medium (Luria-Bertani broth with a
double quantity of yeast extract) and washed twice in RPMI 1640 (Life
Technologies) (3500 3 g, 10 min) before inoculation of the mice.
Mice infection
For i.n. infection, mice were anesthetized with a mixture of xylazine (9 mg/kg)
and ketamine (36 mg/kg) in PBS before being inoculated i.n. with 2 3 104
CFU wt or mCherry-expressing B. melitensis in 30 ml PBS. Control ani-
mals were inoculated with the same volume of PBS. The infectious doses
were validated by plating serial dilutions of the inoculums. At the selected
time postinfection (p.i.), mice were sacrificed by cervical dislocation.
Immediately after sacrifice, spleen, liver, and lung cells were collected for
bacterial count, flow cytometry, and/or microscopic analyses.
The i.p. infection technique used as a comparison with our i.n. model was
described previously (35). Briefly, 23 104 CFU wt or mCherry-expressing
B. melitensis in 500 ml of PBS were injected i.p. without anesthesia.
Antibiotic treatment
Antibiotic treatment was administered to immunized and control mice for
2 wk. The oral treatment was a combination of rifampicin (12 mg/kg) and
streptomycin (450 mg/kg) (adapted from Ref. 17) prepared fresh daily and
given in the drinking water. To ensure that the antibiotic treatment was
effective, some mice from each group were sacrificed 1 wk prior to the
challenge, and the CFU counts were evaluated in the spleen.
Anti IL-17A treatment
Neutralizing Abs against IL-17A (clone 17F3) or the recommended isotype
control MOPC-21 (Bio X Cell) were administrated by i.p. injection
(200 mg/200 ml) 1 h before the i.n. Brucella challenge and at 2, 6, and 12 d
after the challenge. In addition, to saturate the lungs, mice received
50 mg/20 ml Abs against IL-17A or the isotype control by i.n. inoculation
immediately after the i.n. Brucella challenge.
Bacterial count
Spleens, livers, and lungs were crushed and transferred to PBS/0.1% Triton
X-100 (Sigma-Aldrich). We performed successive serial dilutions in RPMI
1640 to obtain the most accurate bacterial count and plated them onto 2YT
medium. The CFU were counted after 5 d of culture at 37˚C. For bacterial
counts in the blood, 75 ml blood was collected from the tail into hepa-
rinized capillary tubes at selected time points and diluted in PBS/0.1%
Triton X-100 (Sigma-Aldrich). Serial dilutions were prepared in RPMI
1640 and plated onto 2YT medium. The CFU were counted after 5 d of
culture at 37˚C.
Cytofluorometric analysis
As described previously (17), spleens were harvested, cut into small pieces,
and incubated for 30 min at 37˚C with a mix of DNase I fraction IX
(Sigma-Aldrich) (100 mg/ml) and 1.6 mg/ml collagenase (400 M and
l U/ml). Spleen cells were washed, filtered, and incubated with saturating
doses of purified 2.4G2 (anti-mouse FcR; American Type Culture Col-
lection) in 200 ml PBS, 0.2% BSA, and 0.02% NaN3 (FACS buffer) for
20 min at 4˚C to prevent Ab binding to the FcR. Various fluorescent mAb
combinations in FACS buffer were used to stain 3–5 3 106 cells. We
acquired the following mAbs from BD Biosciences: FITC-coupled 145-
2C11 (anti-CD3ε), FITC-coupled M1/70 (anti-CD11b), FITC-coupled 1A8
(anti-Ly6G), PE-coupled GL3 (anti– TCR-g/d), PE-coupled RM4-5 (anti-
CD4), PE-coupled 53-6.7 (anti-CD8a), PE-coupled PK136 (anti-NK1.1),
biotin-conjugated RB6-8C5 (anti-Gr1), streptavidin PE, allophycocyanin-
coupled 1-A/1-E (anti-MHC class II [MHCII]), and allophycocyanin-
coupled BM8 (anti-F4/80). The cells were analyzed on a FACSCalibur
cytofluorometer. Dead cells and debris were eliminated from the analysis
according to size and scatter.
Intracellular cytokine staining
For intracellular staining, spleen cells were incubated after DNase-
collagenase treatment for 4 h in RPMI 1640, 10% FCS with 1 ml/ml
Golgi Stop (BD Pharmingen) at 37˚C, under 5% CO2. After washing
with FACS buffer and staining for cell surface markers, cells were fixed in
PBS/1% PFA for 15–20 min at 4˚C. They were permeabilized for 30 min
using a saponin-based buffer (103 Perm/Wash in FACS buffer; BD
Pharmingen) and stained with allophycocyanin-coupled XMG1.2 (anti–
IFN-g; BD Biosciences). After final fixation in PBS/1% PFA, cells were
analyzed on a FACSCalibur cytofluorometer. No signal was detectable
with isotype controls.
In vitro stimulation of lung and spleen cells
Control and immunized mice were sacrificed, and lung and spleen cells were
harvested. Cells were centrifuged and cultured in RPMI 1640 supplemented with
10% FCS, 1% L-glutamine, 1% nonessential amino acids, 1% pyruvate
sodium, and 0.1% gentamicin in six-well plates with 107 cells/well in a
volume of 2 ml. For stimulation, a concentration of 2 3 107 bacteria/ml
heat-killed B. melitensis (HKBr) or 0.5 mg/ml Con A (Sigma-Aldrich) was
used. Cells were incubated for 7 h at 37˚C, 5% CO2. After adding 1 ml/ml
Golgi Stop (BD Pharmingen), the incubation was continued for an addi-
tional 13 h at 37˚C, 5% CO2. Cells were washed and stained for flow
cytometric analysis, as described above.
Immunofluorescence microscopy
Spleens and livers were fixed for 4 h at room temperature (RT) in 2%
paraformaldehyde (pH 7.4), washed in PBS, and incubated overnight at 4˚C
in a 20% PBS-sucrose solution. Lungs were submitted to the same treat-
ment at RT under a vacuum. Tissues were embedded in Tissue-Tek OCT
















compound (Sakura) and frozen in liquid nitrogen, and cryostat sections
(5 mm) were prepared. For staining, tissue sections were rehydrated in PBS
and incubated in a PBS solution containing 1% blocking reagent (Boehringer)
for 20 min before incubation overnight in the same type of solution
containing any of the following mAbs or reagents: DAPI nucleic acid stain
Alexa Fluor 350 or 488 phalloidin (Molecular Probes) to visualize the
structure of the organ and Alexa Fluor 647–coupled BM8 (anti-F4/80;
Abcam), Alexa Fluor 647–coupled M1/70 (anti-CD11b; Abcam), Alexa
Fluor 647–coupled N418 (anti-CD11c; BioLegend), biotin-coupled RB6-
8C5 (anti-Gr1; eBioscience), or purified M-19 (anti-NOS2; Santa Cruz
Biotechnology) to stain the cells of interest. Incubation with a secondary
mAb, Alexa Fluor 488–coupled goat anti-rabbit IgG (Molecular Probes), for
2 h was necessary for the anti-NOS2 mAb. Biotinylated Abs were incubated
for 2 h with Alexa Fluor 350 streptavidin. Detection of Brucella Ag was
performed by incubation overnight with rabbit polyclonal Abs against HKBr
(35), followed by incubation for 2 h with Alexa Fluor 488–coupled goat anti-
rabbit IgG (Molecular Probes). Slides were mounted in Fluoro-Gel medium
(Electron Microscopy Sciences, Hatfield, PA). Labeled tissue sections were
visualized with an Axiovert M200 inverted microscope (Zeiss, Jena, Ger-
many) equipped with a high-resolution monochrome camera (AxioCam HR;
Zeiss). Images (1384 3 1036 pixels, 0.16 mm/pixel) were acquired se-
quentially for each fluorochrome with A-Plan 103/0.25 N.A. and LD Plan-
NeoFluar 633/0.75 N.A. dry objectives and recorded as eight-bit gray-level
*.zvi files. At least three slides/organ were analyzed from three animals, and
the results are representative of two independent experiments.
ELISA
Specific murine IgM, IgA, IgG1, IgG2a, and IgG3 isotypes were determined
by ELISA. Polystyrene plates (Nunc; 269620) were coated with HKBr (107
CFU/ml). After incubation overnight at 4˚C, plates were blocked for 2 h at RT
with 200 ml PBS–3.65% casein. The plates were incubated overnight at 4˚C
with 50 ml serial dilutions of the serum in PBS–3.5% casein. Sera from
unimmunized mice were used as the negative control. After four washes
with PBS, isotype-specific goat anti-mouse HRP conjugates were added
(50 ml/well) at the appropriate dilutions (hIgM from Sigma-Aldrich; hIgA
from Invitrogen; LO-MG1-13 HRPO, LO-MG2a-9 HRPO, and LO-MG3-13
HRPO from LO-IMEX). Plates were incubated for 2 h at RT and washed
four times in PBS before adding 100 ml substrate solution (BD OptEiA) to
each well. After 10 min of incubation at RT in the dark, the enzyme
reaction was stopped by adding 25 ml/well 2 N H2SO4, and absorbance
was measured at 450 nm.
Statistical analysis
We used a (Wilcoxon) Mann–Whitney U test provided by GraphPad Prism
software to analyze our results. Each group of deficient mice was com-
pared with wt mice. The p values were considered to represent a significant
difference.
Results
Intranasal inoculation leads to slow dissemination of Brucella
in the organism
The course of B. melitensis 16M in wt C57BL/6 mice following i.n.
infection was analyzed previously by several research groups (22,
36, 37). However, because the infectious dose, the origin of the
mice, and the conditions in the animal facility could influence the
course of the infection, we began by establishing the kinetics of
infection under our laboratory conditions. Because lungs naturally
contain commensal bacteria, we used a mCherry-Br strain of
B. melitensis 16M displaying kanamycin resistance to evaluate the
Brucella CFU count during the course of infection.
Following i.n. inoculation with 2 3 104 CFU of B. melitensis, wt
C57BL/6 mice were sacrificed at 1, 3, 6, 12, 20, 28, and 50 d p.i.,
and CFU were counted in the lungs, spleen, and liver (Fig. 1A). We
observed that bacteria persisted at the same level in the lungs for
∼12 d and then were progressively eliminated. At 28 d p.i., only
rare mice displayed detectable CFU in the lungs. The dissemination
of Brucella from the lungs to the spleen and liver took ∼3 d. From
6 d p.i., the spleen and liver of the majority of mice displayed
detectable CFU counts, which peaked at 12–28 d p.i. Infection
persisted in the spleen but decreased below the level of detection in
the liver of the majority of mice. Compared with i.p. infection with
the same dose of bacteria, a striking characteristic of i.n. infection
was the slow dissemination from the primary site of infection to
the spleen and liver (38), as well as the absence of detectable bac-
teria in the bloodstream (Fig. 1B). Because our detection limit was
10 CFU/ml, this result suggests that a very small number of bac-
teria travel simultaneously in the bloodstream.
After i.n. administration of 23 104 CFU, flow cytometry analysis
of infected lungs did not reveal a significant modification in the
frequency or number of neutrophils (CD11b+ Ly-6G+ F4/802),
alveolar macrophages (CD11c+ Ly-6G2 F4/80+), and interstitial
macrophages (CD11c2 Ly-6G2 F4/80+) until 12 d p.i. (data not
shown). Intraperitoneal Brucella infection induces dense and easily
detectable granulomas in the spleen and liver, which primarily
contain inducible NO synthase (iNOS)/NOS2+ monocytes and in-
FIGURE 1. Course of B. melitensis infection in organs of wt C57BL/6
mice. Mice were inoculated i.n. with 2 3 104 CFU of mCherry–B. meli-
tensis and sacrificed at the indicated time points. (A) The data represent the
number of CFU/g of lungs (top panel), spleen (middle panel), and liver
(bottom panel). Horizontal gray lines represent the medians. (B) Number
of CFU/ml of blood. n denotes the number of mice used at each time point.
These results are representative of at least three independent experiments.
















flammatory dendritic cells surrounded by granulocytes (35). All of
these cells express high levels of CD11b. Thus, we used iNOS and
CD11b markers to detect the presence of aggregates of activated
myeloid cells in the lung tissue. We observed (Fig. 2A, data not
shown) that lungs of infected mice do not display a greater number
of CD11b+ aggregates compared with lungs of control naive mice.
In addition, the few CD11b+ aggregates present in the lungs of
infected mice are negative for iNOS or the presence of Brucella Ags
(data not shown). Thus, in agreement with reports by other inves-
tigators (39), we conclude that, although nonnegligible CFU levels
are reached, Brucella lung infection does not lead to granuloma
formation during any phase of infection. This suggests that the early
control of Brucella growth in mucosal lung tissue does not induce
or require an inflammatory reaction. To test this hypothesis, we
compared the course of Brucella infection in wt, IL-1R2/2, IL-62/2,
TNF-a2/2, and CCR22/2 [deficient for monocyte recruitment
(40)] C57BL/6 mice (Fig. 3). Mice deficient for IL-1R, IL-6, and
TNF-a or the CCR2-dependent recruitment of monocytes displayed
CFU counts in the lungs similar to those of wt mice during the first
5 d of infection, confirming that the inflammation process does not
seem to be implicated in the early control of Brucella infection in
the lungs. At 12 and 28 d p.i., only TNF-a2/2 mice displayed
significantly higher CFU counts in the organs. IL-1R deficiency had
a slightly significant impact on the spleen only at 28 d p.i.
In drastic contrast to the lungs, colonization of the spleen
(Fig. 2B) and liver (Fig. 2C) was accompanied by CD11b+ iNOS+
granuloma formation. Rabbit polyclonal Abs against HKBr con-
firm the presence of Brucella Ags inside granulomas (Fig. 2D).
Unfortunately, the low frequency of Brucella in organs does not
allow for direct visualization of the bacteria in tissue sections
using the mCherry-expressing strain. Interestingly, the location of
granulomas in the spleen after i.n. infection was clearly different
from their location after i.p. infection. As we reported previously
(35), following i.p. infection, granulomas are mainly located in the
red pulp during the first days of infection and are found in the
white pulp only after 12 d. After i.n. infection, granulomas appear
immediately and only inside the marginal zone and white pulp
(Fig. 2C), suggesting that the localization of granulomas in the red
pulp could be a consequence of the rapid and abrupt infection of
the spleen following i.p. injection.
IFN-gR– and IL-17RA–mediated responses contribute to the
control of primary i.n. infection
The central role of the TLR4/TLR9/MyD88/IL-12 axis in pro-
moting IFN-g–producing CD4+ T cells to control Brucella growth
in the spleen following i.p. infection is well established (14, 16,
35). By comparing the course of i.p. infection in the spleen in wt,
IL-12p352/2, IL-23p192/2, and IL-12p402/2 (deficient for both
FIGURE 2. CD11b+ granulomas in the spleen and liver of
wt C57BL/6 mice. Mice were inoculated i.n. with 2 3 104
CFU of mCherry–B. melitensis and sacrificed at the indicated
times. Localization by immunofluorescence of CD11b+-,
Brucella Ag-, and iNOS-expressing cells in the lungs (A),
spleen (B and D), and liver (C) of naive (cont) and infected
mice at the indicated time points. Panels are color-coded with
the text for DAPI (nucleus staining), phalloidin (actin stain-
ing), or the Ag examined. Data are representative of at least
two independent experiments. r.p., red pulp; w.p., white pulp.
















IL-12 and IL-23) mice, we observed that IL-12p402/2 mice dis-
play higher susceptibility than IL-12p352/2 mice, which suggests
a weakly compensatory role for IL-23 (affecting the IL-17A–
mediated response) in the absence of IL-12p35 (affecting the IFN-
g–mediated response) in the spleen (16). In our i.n. infection
model, we analyzed the impact of this deficiency on the control
of Brucella growth in the lungs, spleen, and liver (Fig. 4A). IL-
23p192/2 mice displayed CFU counts similar to wt mice at all
time points and in all organs tested. IL-12p352/2 and IL-12p402/2
mice displayed enhanced CFU counts in the spleen throughout the
entire course of infection. In drastic contrast to the spleen, IL-
12p35 deficiency only had a transient impact on CFU counts in the
lungs and liver. At 50 d p.i., these mice eliminated Brucella like
wt mice. Only IL-12p40 deficiency leads to long-term uncon-
trolled persistence in the lungs and liver at 50 d p.i. These results
demonstrate that the immune requirements for the control of
Brucella infection are organ-specific and suggest that the IL-23–
dependent IL-17A–mediated response may compensate for the
partial absence of an IFN-g–mediated response to control Brucella
in the lungs and liver.
Then we compared the impact of direct IFN-gR and IL-17RA
deficiencies on the course of i.n. Brucella infection. As reported
previously (41–43), the complete absence of functional IFN-g
signaling leads to high CFU counts in all tested organs (Fig. 4B)
and 100% mortality after 35 d p.i. (Fig. 5A). By comparison, the
impact of IL-17RA deficiency appears to be limited to higher CFU
counts in the lungs during the early stages of infection (Fig. 5),
without any associated mortality (data not shown). Interestingly,
the impact of IL-17RA deficiency is already pronounced at 5 d p.i.
At that point in time, IFN-gR signaling deficiency has no de-
tectable impact in the lungs, suggesting that the IL-17RA–medi-
ated response starts before the IFN-gR–mediated response in the
lungs and could constitute the first line of defense against Brucella
infection.
High mortality in IFN-gR–deficient mice in response to
Brucella infection is associated with dramatic neutrophilia
The fatal course of Brucella infection in all mice displaying a
deficiency in IFN-g signaling [IFN-g2/2 (41, 43), IRF12/2 (42)
mice] supports the idea that IFN-g plays a pivotal role in medi-
ating a protective immune response. However, the absence of
mortality in RAG12/2 (16), MyD882/2 (14), and IL-12p352/2
(16) mice is surprising because T cells are described as the main
producer of IFN-g during chronic Brucella infection (14, 16), and
MyD88 (14) and IL-12p35 (16) have been closely implicated in
IFN-g induction. This shows that mortality results only from the
complete absence of IFN-g and is not proportional to its level. We
observed that CFU levels in organs were nearly similar in CD3ε2/2
and IFN-gR2/2 mice (Fig. 5B), but only IFN-gR2/2 mice died
(Fig. 5A), suggesting that the lack of control of Brucella growth in
the organs is not the only reason for IFN-gR deficiency–associated
mortality.
To reconcile this enigma, we examined the lungs, spleen, and
liver of wt, IL-12p352/2, CD3ε2/2, and IFN-gR2/2 mice 35 d
after i.n. infection by in situ fluorescent microscopy. We observed
that only IFN-gR2/2 infected mice displayed a dramatic recruit-
ment of Gr1+ cells in tissues (Fig. 6A for lungs, Supplemental
Fig. 1 for comparison of the lungs, spleen, and liver). Flow
cytometry analysis identified Gr1+ cells in the spleen as neutro-
phils, as demonstrated by their typical cell surface phenotype:
Ly-6G+ F4/802 MHC-II2 CD11b+ (Supplemental Fig. 2). This
dramatic neutrophilia was not correlated with the observation of a
higher frequency of IL-17A+ cells by flow cytometry in the spleen
of IFN-gR2/2 infected mice (data not shown), suggesting that a
compensatory IL-17A–mediated response is not implicated in
mortality. Interestingly, the IFN-gR deficiency strongly affected
the cellular composition of the granulomas in the liver (Fig. 6B)
and spleen (data not shown). We showed previously (35) that
granulomas induced by Brucella infection are primarily composed
of iNOS+ monocytes (CD11b+ CD11c2 F4/80low) and inflamma-
tory dendritic cells (CD11b+ CD11c+ F4/80high) with few neu-
trophils (CD11b+ Ly-6G+/GR1+). We observed a similar cellular
composition of the granulomas in the liver (Fig. 6B) and spleen
(data not shown) after i.n. infection in wt and IL-12p352/2 mice,
with only a partial reduction in iNOS staining in IL-12p352/2
mice. In contrast, IFN-gR2/2 infected mice displayed large
granulomas dominated by iNOS2 CD11b+ Gr1+ CD11c2 F4/802
cells. These neutrophil-rich granulomas did not seem able to re-
strict Brucella dissemination because they were correlated with
high CFU counts in the blood from all IFN-gR2/2 infected mice
(Fig. 6C). Note that a kinetic analysis showed that Brucella be-
comes detectable in the blood of IFN-gR2/2 mice only starting at
20 d p.i. (data not shown). No bacteria are detected during the
course of infection in wt mice (Fig. 1B) and IL-12p352/2 infected
mice (data not shown), and only a small fraction of infected
CD32/2 mice display a small number of bacteria in the blood
(Fig. 6C). As a whole, these results demonstrate that the high
FIGURE 3. Course of B. melitensis in organs of wt, IL-1R–deficient,
IL-6–deficient, TNF-a–deficient, and CCR2-deficient C57BL/6 mice. wt
and deficient mice were inoculated i.n. with 2 3 104 CFU of mCherry–
B. melitensis and sacrificed at the indicated time points. The data represent
the number of CFU/g of lung (top panel), spleen (middle panel), and liver
(bottom panel). Horizontal lines represent the medians. n denotes the
number of mice used for each lineage at each time point. These results are
representative of at least two independent experiments. *p , 0.05, **p ,
0.01, ***p , 0.001.
















mortality observed in IFN-gR2/2 mice following B. melitensis
infection is associated with dramatic neutrophilia leading to
multiple organ failure and a major alteration in granuloma for-
mation associated with the persistence of bacteria in the blood.
Contribution of lymphocyte subsets to the control of Brucella
growth after primary i.n. infection
To determine the lymphocyte populations implicated in the con-
trol of primary i.n. Brucella infection, we compared the course
of infection in various strains of C57BL/6 mice genetically defi-
cient for key genes affecting specific lymphocyte subsets.
The absence of a/b+ or g/d+ T lymphocytes leads to a lack of
Brucella control in the lungs (Fig. 7A). TCR-b deficiency affects
early Brucella control in the lungs and late control in all organs. In
contrast, TCR-d deficiency strongly impairs early Brucella growth
in the lungs but has only a transient impact on spleen and liver
bacterial loads at 12 d p.i., with no impact on late control at 28 and
50 d p.i. Comparison of TAP1 and MHCII deficiencies (Fig. 7B)
suggests that CD8+ a/b+ T lymphocytes only participate in the
early control of Brucella in the lungs and for a short period of
time in the spleen at 28 d p.i. In striking contrast, MHCII defi-
ciency affecting CD4+ a/b+ T lymphocytes fully abrogates Brucella
control in all organs from 12 to 50 d p.i., thus confirming the
crucial role played by CD4+ a/b+ T lymphocytes in the protective
immune response against chronic Brucella infection (Fig. 7B).
Thus, although g/d+ T cells and CD8+ a/b+ T cells constitute a
first line of defense in mucosal lung tissue, CD4+ a/b+ T cells
appear to be involved in the later control of infection in all organs.
Comparison of the cell surface phenotype of IFN-g–producing
cells in the spleen of wt mice following i.p. and i.n. Brucella in-
fection showed that CD4+ a/b+ T lymphocytes are the dominant
IFN-g–producing cells at all times during infection (Fig. 8). In
contrast to i.p. infection, we did not observe an early peak in
IFN-g–producing g/d+ T lymphocytes, NK, or CD8+ a/b+
T lymphocytes during i.n. infection, suggesting that early activa-
tion of these cells during i.p. infection could be a consequence of
the rapid and massive dissemination of Brucella in the spleen.
As we observed previously in an i.p. model (16), the course of
Brucella infection appears to be similar in the lungs, spleen, and
liver of i.n. infected wt, AID2/2 (deficient for activation-induced
deaminase-mediated isotype switching), and MuMT2/2 (deficient
for B lymphocytes) C57BL/6 mice at all time points tested (Fig. 9).
This demonstrates that Abs do not play a crucial role in the control
of primary Brucella infection in our i.n. infectious model.
Intranasal Brucella infection induces protective memory acting
in the lung
To gain further insight into the secondary immune response against
Brucella, wt mice received i.n. administrations of 30 ml of PBS
alone (control mice) or 2 3 104 CFU of the wt (nonfluorescent)
strain of B. melitensis. At 28 d p.i., both groups were treated daily
with a combination of antibiotics (see Materials and Methods) for
2 wk to eliminate the Brucella. As shown previously (17), this treat-
ment led to the complete elimination of Brucella in all tested organs
of the infected mice. After a rest period of 2 wk, control mice and
previously infected mice were challenged with an mCherry-Br strain
of B. melitensis. Kinetic analysis of the CFU counts in the lungs,
spleen, and liver (Fig. 10A) showed that the previously infected
animals displayed a greater ability to control Brucella infection. The
CFU counts in the lungs had already decreased by .1 log at 6 d. In
contrast to primary infected mice, a majority of the secondary in-
fected mice did not display bacteria in the spleen at 12 and 28 d p.i.
FIGURE 4. Course of B. melitensis in organs
of wt, IL-12p35–deficient, IL-12p40–deficient,
IL-23p19–deficient (A), IFN-gR–deficient, and
IL-17RA–deficient (B) C57BL/6 mice. wt and
deficient mice were inoculated i.n. with 23 104
CFU of mCherry–B. melitensis and sacrificed at
the indicated time points. The data represent
the number of CFU/g of lung (top), spleen
(middle), and liver (bottom). Bars represent the
medians. n denotes the number of mice used for
each lineage at each time point. These results
are representative of at least three independent
experiments. *p , 0.05, **p , 0.01, ***p ,
0.001.
















It is interesting to note that i.n. infection protects against i.n. and i.p.
challenges (Fig. 10B). On the whole, these results demonstrate that
Brucella infection induces development in the lung of a protective
memory that limits or impairs the dissemination of bacteria from
the lung to the spleen and liver.
CD4+ and CD8+ a/b+ T cells are able to control secondary i.n.
Brucella infection
Characterization of the lymphocyte populations and Th cell po-
larization necessary to control secondary mucosal Brucella in-
fection constitutes the first step in understanding the underlying
mechanisms of the protective immune response and developing a
rational strategy to select a protective candidate vaccine against
brucellosis. Previous studies by our group using an i.p. B. meli-
tensis infectious model with the same B. melitensis strain (17)
showed that genetic deficiencies leading to a lack of CD4+ T cells
(MHCII2/2 mice), B cells (MuMT mice), or IL-12 (IL-12p352/2
mice) completely impaired the ability of mice to develop a pro-
tective secondary immune response limiting infection of the
spleen.
wt, CD3ε2/2, TCR-b2/2, TCR-d2/2, TAP12/2, MHCII2/2,
MuMT2/2, IL-12p352/2, IL-17RA2/2 and IL-23p192/2 mice
infected with wt B. melitensis 28 d previously and treated
with antibiotics as described previously were challenged with
mCherry–B. melitensis. Naive wt mice were used as the internal
control. Fig. 11 shows the CFU counts in the spleen at 28 d
postchallenge. We observed that only the spleen of CD3ε 2/2 and
TCR-b2/2 mice displayed a lack of control of Brucella growth
compared with wt mice. They were also the only mice to present
persisting infection in the lungs following the Brucella challenge
(data not shown). In striking contrast with an i.p. infection model
(17), deficiencies in MHCII, IL-12p35, or B cells do not signifi-
cantly impair the development of protective immune memory.
The negligible role of B lymphocytes in the control of an i.n.
secondary challenge is not due to an impaired ability of i.n. in-
fection–induced specific Abs to control Brucella. This is demon-
strated by the fact that i.p.– and i.n.–infected mice displayed
specific circulating Abs against Brucella at 28 d p.i. (Supplemental
Fig. 3A) and were equally able to control the bacteria counts in the
blood after i.p. challenge with 5 3 107 CFU of B. melitensis
(Supplemental Fig. 3B).
The efficient control of secondary Brucella infection observed in
IL-12p352/2 mice challenges the idea that the IFN-g–mediated
response is crucial to Brucella control. To determine whether the
IL-17A–mediated response compensates for the lack of the IL-12–
dependent IFN-g–mediated response in IL-12p352/2 immunized
mice, we tested the impact of IL-17A neutralization in these mice.
After i.n. challenge, wt and IL-12p352/2 immunized mice were
treated with neutralizing Abs against IL-17A, as indicated in
Materials and Methods. We observed (Fig. 11B) that this treat-
ment abolishes the protection in IL-12p352/2 challenged mice but
not in wt mice. A similar treatment with the isotype control had no
detectable impact (data not shown). Taken together, these results
suggest that the IL-17A–mediated response can compensate for
the reduced IFN-g–mediated response in IL12p352/2 mice to
control a Brucella challenge. Unfortunately, a similar experiment
would not be feasible in IFN-gR2/2 mice because the complete
absence of the IFN-g signaling pathway leads to the death of all
Brucella-infected mice around 35–40 d p.i., even with oral anti-
biotic treatment (described in Materials and Methods section)
starting at 20 d and reinforced by i.p. injection of the antibiotic
(data not shown).
Finally, to identify the IFN-g– and IL-17A–producing cells in
the lung and spleen during the memory response, we performed a
kinetic analysis of the cytokines by flow cytometry in challenged
wt mice. In the absence of in vitro restimulation, we did not detect
IFN-g and IL-17A in the lung and spleen cell populations from
challenged mice at any time point tested (data not shown), which
suggests that the levels of these cytokines are very low in vivo. To
solve this problem, we stimulated the lung and spleen cells from
control and immunized wt mice overnight in vitro with HKBr or
0.5 mg/ml of Con A (Fig. 12A). HKBr stimulation induces IFN-g+
cells in the spleen of immunized mice but not control mice. These
cells are a/b+ T cells (Fig. 12B) and mainly CD4+ (data not
FIGURE 5. Comparison of B. melitensis infection among wt, IL12p35-
deficient, CD3–deficient, and IFN-gR–deficient C57BL/6 mice. wt and
deficient mice were infected i.n. with 2 3 104 CFU of mCherry-B. meli-
tensis. (A) Survival curve of wt and deficient mice (n = 10). (B) Infected wt
and deficient mice were sacrificed at 35 d p.i. The data represent the
number of CFU/g of lung (top panel), spleen (middle panel), and liver
(bottom panel). Horizontal gray lines represent the medians. n denotes the
number of mice used for each lineage. These results are representative of at
least two independent experiments. *p , 0.05, ***p , 0.001.
















shown). Similar stimulation of lung cells did not lead to detectable
IFN-g production. Unspecific Con A stimulation is required to
induce IFN-g+ cells in lung cells. These cells also appear to be
a/b+ T cells (Fig. 12B) and mainly CD4+ (data not shown). Lung
cells from immunized mice display a higher frequency of IFN-g+
cells upon Con A stimulation compared with control mice, sug-
FIGURE 6. Immunofluorescent microscopic analysis of lungs and liver of wt, IL-12p35–deficient, and IFN-gR–deficient C57BL/6 mice. wt, IL-12p35–
deficient, CD3-deficient, and IFN-gR–deficient mice were injected i.n. with 2 3 104 CFU of mCherry–B. melitensis and sacrificed at 35 d p.i. (A) Immunohis-
tofluorescence of lung from wt (upper panel) and IFN-gR–deficient mice (bottom). Panels are color-coded with the text for phalloidin (actin staining) or the Ag
examined (Gr1). (B) Phenotypic analysis of granuloma in the liver of infected wt, IL-12p35–deficient, and IFN-gR–deficient mice. Panels are color-coded with the
text for DAPI (nucleus staining) or the Ag examined. (C) Number of CFU/ml of blood in wt, IL-12p35–deficient, CD3-deficient, and IFN-gR–deficient mice.
Horizontal gray line represents the median. n denotes the number of mice used for each lineage. Data are representative of at least two independent experiments.
FIGURE 7. Course of B. melitensis in or-
gans of wt, TCR-b–deficient, TCR-d–deficient,
TAP1-deficient, and MHCII-deficient C57BL/6
mice. (A and B) wt and deficient mice were
inoculated i.n. with 2 3 104 CFU of mCherry–
B. melitensis and sacrificed at the indicated time
points. The data represent the number of CFU/g
of lung (top panels), spleen (middle panels), and
liver (bottom panels). Horizontal gray lines
represent the medians. n denotes the number of
mice used for each lineage at each time point.
These results are representative of at least three
independent experiments. *p , 0.05, **p ,
0.01, ***p , 0.001.
















gesting that Brucella infection induces specific CD4+ a/b+ T cells
in the lung. Unfortunately, under the same experimental condi-
tions, we did not detect IL-17A–producing cells in response to
HKBr or Con A, suggesting that the frequency of these cells is
extremely low or that these cells are lost during the flow cytometry
protocol.
A comparison of immune effector mechanisms essential to the
control of Brucella infection in i.p. and i.n. infection models is
shown in Fig. 13.
Discussion
A growing number of clinically relevant infectious diseases are
caused by pathogen persistence in the host and require long-lasting
and costly therapies (44). Chronic infection is generally the con-
sequence of the ability of a pathogen to escape the adaptive im-
mune response and generate a microenvironment in which it can
survive. Therefore, it is crucial to neutralize such pathogens before
they disseminate and colonize the host. The major point of entry
for many pathogens is the gastrointestinal or respiratory tract, or
the genital mucosa (reviewed in Ref. 45), suggesting that mucosal
protective immune responses must be induced to counteract
pathogen dissemination. However, the ways by which mucosal
immunization could generate protective frontline immunity
against pathogens remain largely undefined. Brucella establishes a
stealthy infection in mice and constitutes an interesting experi-
mental model that can be used to analyze the relationships be-
tween hosts and intracellular stealth pathogens (46, 47). Although
the aerosol route is a common cause of infection in nature (1), a
relatively limited number of Brucella studies (20, 22, 36, 37, 48,
49) investigated the protective immune response following respi-
ratory infection. In this study, we analyzed the progression of
B. melitensis in the lungs, spleen, and liver of C57BL/6 mice, as
well as the nature of the protective immune response following
primary and secondary i.n. infection, and compared them with our
results (16, 17, 35, 38) obtained in the classical i.p. infection model.
In contrast to i.p. infection (35, 38), i.n. infection does not lead
to the rapid dissemination of Brucella in the spleen and liver or to
detectable and prolonged persistence of Brucella in the blood.
This could explain why Brucella-induced granulomas in the
spleen immediately appeared primarily in the white pulp in this
i.n. model and not in the red pulp as previously described following
i.p. infection (35). We hypothesize that i.p. infection saturates the
marginal zone filter of the spleen consisting of marginal zone
macrophages and dendritic cells, thus allowing for the infection of
red pulp F4/80+ macrophages. These observations suggest that the
route of infection could potentially alter the tissue localization of
the bacteria and the phenotype of the primary infected cells.
The cytokines IL-1, IL-6, and TNF-a are sometimes referred to
as the inflammatory triad because they are key mediators of local
and systemic inflammatory responses. Impaired IL-1 (50, 51),
IL-6 (52–54), and TNF-a (55–57) signaling causes enhanced
susceptibility of mice to infection with various pathogens. Sur-
prisingly, in our experimental model, we observed that early
Brucella control in the lungs is not affected by IL-1R, IL-6, or
TNF-a deficiency. Furthermore, during the late phase of control,
only TNF-a deficiency strongly affected CFU counts of Brucella
in the organs. In keeping with this observation, Brucella was re-
cently shown to induce weak IL-1b, IL-6, and TNF-a production
in lung alveolar macrophages compared with peritoneal macro-
phages (58). The chemokine receptor CCR2 has been implicated
in the recruitment of inflammatory monocytes during infection
(40). CCR2 deficiency impaired development of a protective im-
mune response in several infectious models (40, 59, 60). We ob-
served that CCR2 deficiency had no impact on the course of
Brucella infection in the lungs, liver, or spleen at all time points
tested. We also did not detect recruitment of inflammatory cells in
FIGURE 8. IFN-g production in the spleen of wt
C57BL/6 mice after B. melitensis infection. wt mice were
infected i.n. or i.p. with 2 3 104 CFU of mCherry–
B. melitensis and sacrificed at the indicated time points.
Spleen cells were collected and analyzed by flow cytom-
etry. Cells were gated according to the size and scatter to
exclude dead cells and debris for analysis. Number (mean6
SEM) of IFNg+ cells (A), CD3+ CD4+ IFNg+ cells (B),
CD3+ CD8+ IFNg+ cells (C), NK1.1+ CD32 IFNg+ cells
(D), and gd+ IFNg+ cells (E) per 106 spleen cells acquired
at different times p.i. Squares and dashed lines indicate the
level of IFN-g production by each cell type in naive mice.
These results are representative of at least two independent
experiments.
















the lungs during Brucella infection by flow cytometry (data not
shown) or modification of the cellular organization, such as the
formation of granulomas, by microscopy during the period of
infection. These results suggest that control of Brucella growth
in the lungs does not involve the development of a strong
local inflammatory response or the recruitment of inflammatory
monocytes.
Initially, the IL-17RA–mediated response was primarily asso-
ciated with the host defense against extracellular pathogens
(reviewed in Ref. 61). However, a growing number of recent
studies suggest that this response is also involved in the control
of intracellular microorganisms, such as Listeria monocytogenes,
Salmonella enterica, and Mycobacterium tuberculosis (reviewed
in Refs. 62, 63). In the lungs, IL-17Awas reported to act primarily
on nonhematopoietic cells, such as epithelial cells, endothelial
cells, and fibroblasts (reviewed in Ref. 63), to promote the pro-
duction of numerous proteins with antimicrobial properties and
chemokines that attract neutrophils. Although first identified in
CD4+ T cells, IL-17A can also be produced by CD8+ T cells and
innate cells, such as g/d+ T cells, invariant NKT cells, neutrophils,
and innate lymphoid cells (63). There have been few studies of the
function of IL-17A–mediated responses in immunity to Brucella
organisms. In a classical i.p. infection model, we reported that IL-
23p19 deficiency, which is known to reduce the IL-17A produc-
tion response (64), does not significantly affect the control of
Brucella in the spleen but can partially compensate for IL-12p35
deficiency (16). In the present work, we observed that, following
i.n. infection, IL-17RA and IL-23p19 deficiency only had minor
effects on CFU counts in the spleen and liver throughout infec-
tion. In contrast, IL-17RA2/2 mice displayed an important lack of
FIGURE 9. Course of B. melitensis in organs of wt, RAG1-deficient,
AID-deficient, and MuMT-deficient C57BL/6 mice. wt and deficient mice
were inoculated i.n. with 2 3 104 CFU of mCherry–B. melitensis and sac-
rificed at the indicated time points. The data represent the number of CFU/g
of lung (top panel), spleen (middle panel), and liver (bottom panel). Hori-
zontal gray lines represent the medians. n denotes the number of mice used
for each lineage at each time point. These results are representative of at least
three independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001.
FIGURE 10. Kinetic analysis of the course of infection in wt C57BL/6
mice previously immunized with live B. melitensis. wt C57BL/6 mice were
immunized i.n. with live B. melitensis (2 3 104 CFU) and treated with
antibiotics, as described in Materials and Methods. (A) Naive (primary
infected group) and immunized (secondary infected group) wt mice were
challenged i.n. with 2 3 104 CFU of mCherry–B. melitensis and sacrificed
at 6, 12, and 28 d p.i. The data represent the number of CFU/g of lung,
spleen and liver. (B) Naive and immunized wt mice were challenged i.n. or
i.p. with 2 3 104 CFU of mCherry–B. melitensis and sacrificed at 28 d
postinfection. The data represent the number of CFU/g of spleen. Hori-
zontal gray lines represent the medians. n denotes the number of mice used
for each lineage at each time point. These results are representative of at
least two independent experiments. **p , 0.01, ***p , 0.001.
















control in the lungs during the early stages of infection, until 12 d
p.i. Interestingly, during the same period, IL-23p19 and IFN-gR
deficiency had no or only minor effects on CFU counts of Brucella
in the lungs. These results suggest that the IL-17RA–mediated
response constitutes the first line of defense against Brucella in the
lungs. IL-17A production is generally considered strictly depen-
dent on IL-23, but reduced IL-17A production can still be detected
in IL-23p192/2 mice (27). The absence of an effect of IL-23p19
deficiency in our model suggests that low counts of IL-17A could
be sufficient to mediate Brucella control in the lung. The IFN-g–
mediated response seems to develop late in the lungs, and an IL-
17RA–mediated response may compensate for reduced IFN-g
production due to IL-12p35 deficiency, as suggested by the fact
that wt and IL-12p352/2 mice, but not IL-12p402/2 mice, control
the infection at later stages in the lungs. A similar compensatory
phenomenon is observed in the liver. Unfortunately, presumably
due to the stealthy nature of Brucella infection, we failed to detect
IL-17A+ cells in the lungs by flow cytometry and, thus, to identify
their source during primary or secondary infection. However, we
observed that TCR-d and TAP1 deficiency, but not MHCII defi-
ciency, also affected early Brucella control in the lungs, sug-
gesting that these cells could be a potential source of IL-17A in
our model. In keeping with this observation, IL-17 production by
g/d T cells was reported in a Brucella model (65) and in several
other pulmonary infectious models (66–68).
Studies carried out in i.p. infectious models clearly established
the crucial role of IFN-g–secreting CD4+ T cells in the primary
control of Brucella infection (16, 35, 41–43). We confirmed this
key role in our i.n. model. From 12 d p.i., IFN-gR and MHCII
deficiency led to a dramatic lack of Brucella control in the lungs,
spleen, and liver. Moreover, we demonstrated that mortality
associated with a deficiency in IFN-g signaling is linked to un-
controlled Brucella growth in tissues and probably to severe
neutrophilia, which causes multiple organ failure. We failed to
FIGURE 11. Comparison of protection in wt and deficient C57BL/6
mice previously immunized with live B. melitensis. wt, CD32/2, TCR-b2/2,
TCR-d2/2, TAP12/2, MHCII2/2, MuMT2/2 (A), IL-12p352/2, IL-17RA2/2,
and IL-23p192/2 (B) C57BL/6 mice were immunized i.n. with live wt
B. melitensis (2 3 104 CFU) and treated with antibiotics, as described in
Materials and Methods. Naive (primary infected group) and immunized
(secondary infected group) wt mice were challenged i.n. with 23 104 CFU
of mCherry–B. melitensis and sacrificed at 28 d p.i. Immediately after the
challenge, a group of immunized wt and IL-12p352/2 mice was treated
with anti–IL-17A, as described in Materials and Methods. The data rep-
resent the number of CFU/g of spleen. Horizontal gray lines represent the
medians. n denotes the number of mice used for each lineage at each time
point. These results are representative of at least two independent exper-
iments. *p , 0.05, **p , 0.01.
FIGURE 12. In vitro stimulation of lung and spleen cells from wt
C57BL/6 mice previously immunized with live B. melitensis. wt C57BL/6
mice were injected i.n. with PBS (control mice) or live B. melitensis (2 3
104 CFU) (immunized mice) and treated with antibiotics, as described in
Materials and Methods. Control and immunized mice were sacrificed, and
lung and spleen cells were recovered for overnight in vitro stimulation with
PBS (unstimulated), 2 3 107 CFU/ml of HKBr, or 0.5 mg/ml of Con A.
Cells were analyzed by flow cytometry for TCR-b and IFN-g expression.
(A) Mean number of IFN-g+ cells/106 cells acquired. Each data point
represents the median value obtained from four individual lungs and
spleens. (B) Representative TCR-b versus IFN-g dot plots from lungs and
spleens of the group indicated. Numbers represent the number of IFN-g+
TCR-b+ T cells/105 or 106 cells acquired, as indicated. The data are rep-
resentative of two independent experiments. *p , 0.05, **p , 0.01.
















reduce Brucella-induced mortality in IFN-gR2/2 mice by re-
peated administration of depleting Abs, such as 1A8 or GR1
specific to neutrophils (data not shown). Most likely, this can be
attributed to the chronic nature of Brucella infection, which leads
to continuous recruitment of new neutrophils. This neutrophilia is
not associated with a compensatory IL-17A–mediated response,
because we did not detect a higher frequency of IL-17A+ cells in
the spleen of infected IFN-gR2/2 mice by flow cytometry com-
pared with infected wt mice (data not shown). Likewise, cutane-
ous and musculoskeletal inflammation observed following i.p.
Brucella infection in IFN-g2/2 mice is independent of the Th17
response (69). In an Ehrlichia muris infection model (70), IFN-g
was shown to control infection by directly promoting the differ-
entiation of myeloid cells into monocytes. In the absence of IFN-g
signaling, E. muris infection only promotes the expansion of
neutrophils, which do not play a protective role during Brucella
infection (71) and are generally associated with massive tissue
damage, particularly in the lungs (reviewed in Ref. 72). In our i.n.
infectious model, the absence of IFN-gR was associated with a
drastic alteration in the granuloma composition, which appeared
to primarily contain neutrophils, and a lack of tissue confinement
of Brucella, as demonstrated by the high levels of bacteria ob-
served in the blood of IFN-gR2/2 mice during chronic infection
but not during the early phases of infection. In summary, our re-
sults strongly suggest that the protective role of IFN-g against
Brucella infection is primarily limited to the chronic phase of
infection and may even have been overestimated based on the
exceptional mortality associated with IFN-g deficiency (41, 43).
IFN-g is clearly crucial to late Brucella control in all organs, but is
not sufficient, because we observed, in an i.p. infection model
(16), that a similar frequency of IFN-g–producing CD8+ T cells
does not replace IFN-g–producing CD4+ T cells to control Bru-
cella growth in the spleen following primary infection.
To identify potential protective immune markers to select can-
didate vaccines against brucellosis, we previously attempted to
characterize the cells and signaling pathways involved in the gen-
eration of a protective immune memory response following i.p.
priming with live B. melitensis (17). We showed that IL-12p35,
MHCII, and B cell deficiency completely impair the control of
secondary Brucella infection in the spleen. Using a similar ap-
proach in the i.n. infection model, we analyzed the course of
secondary B. melitensis infection. Secondary infections appear to
be primarily controlled in the lung, because the majority of im-
munized mice displayed a 10-fold reduction in CFU counts in the
lungs at 6 d p.i. compared with primary infected mice, and 60%
presented no detectable bacteria in the spleen or liver at 12 d.
Using genetically deficient mice, we observed that CD3 and TCR-b
deficiency, but not TCR-d or B cell deficiency, completely ab-
rogates protection in the spleen, thus demonstrating that a/b+
T cells constitute the core of the adaptive immune system impli-
cated in protective immunity against Brucella. Because the se-
lective absence of CD4+ a/b+ T cells (in MHCII2/2 mice) or
CD8+ a/b+ T cells (in TAP12/2 mice) does not affect the efficacy
of the secondary protective immune response, we conclude that
these two populations are equally able to mediate protective im-
mune responses against an i.n. Brucella challenge. Thus, although
Brucella display immune escape mechanisms that affect CD8+
T cell activity (73, 74), memory CD8+ T cells seem to be able to
compensate for the absence of memory CD4+ T cells and, thus, to
control secondary i.n. infection with Brucella. We also observed
that IL-12p35, IL-17RA, and IL-23p19 deficiency did not signif-
icantly affect protective immunity against secondary i.n. infection.
However, protection in IL-12p352/2 mice is completely abolished
by injecting neutralizing IL-17A–specific Abs, which suggests
that the IL-17A–mediated response is able to compensate for the
reduced IFN-g–mediated response in IL-12p352/2 mice. In keep-
ing with this observation, live oral brucellosis vaccines were
reported to stimulate IFN-g–mediated and IL-17A–mediated re-
sponses in mice (75). Oral immunization with attenuated DznuA
and RB51 strains of B. melitensis induces protection in IFNg2/2
BALB/c mice against an i.n. challenge with a virulent B. meli-
tensis strain. Neutralization of IL-17A in IFNg2/2 mice reduces
the protection conferred by the RB51, but not by the DznuA,
vaccine strain. Thus, the control of secondary i.n. Brucella in-
fection seems to be characterized by a redundancy of protective
immune mechanisms and, consequently, a great robustness to
selective deficiencies of IL-17A–mediated and IFN-g–mediated
response or T cell subsets (g/d+ T cells, CD4+ a/b+ T cells, CD8+
a/b+ T cells).
We observed previously (38) that, following i.p. inoculation,
Brucella display a brief extracellular phase in the blood and then
are able to invade erythrocytes and to persist for several weeks in
FIGURE 13. Comparison of the i.p. and i.n.
Brucella infection models. The figure shows
the comparison of the immune mechanisms
and lymphocyte populations implicated in the
control of primary and secondary infection in
the i.p. and i.n. infectious models. Note that the
identity of the cytokine-producing cells in the
lung remains to be determined.
















the bloodstream. Circulating specific Abs present in immunized
mice are able to neutralize Brucella before erythrocyte invasion and,
thus, to reduce Brucella dissemination to organs (38). Surprisingly,
we observed that protective immunity against an i.n. challenge is not
significantly affected by a B cell deficiency. We hypothesize that,
following i.n. infection, Brucella disseminate from lung tissue inside
myeloid phagocytic cells and, thus, avoid neutralizing Abs, a result
that is in keeping with the observation that Brucella are rapidly
found in dendritic cells and alveolar macrophages in lung-draining
lymph nodes following primary i.n. infection (39). Thus, the control
of i.n. Brucella infection appears to be primarily dependent on cel-
lular immunity and independent of humoral immunity.
As a whole, our work highlights the importance of analyzing the
protective immune response in experimental models using natural
routes of infection. By comparing i.p. and i.n. infection models, we
have shown that the location of bacteria in organs and the effector
immune mechanisms required to control primary and secondary
infection are strongly dependent on the route of inoculation (sum-
marized in Fig. 13). Our results challenge the idea that the Th1
response mediated by CD4+ T cells is indispensable to the devel-
opment of a protective memory response against Brucella infection.
In our i.n. infection model, we found that CD8+ T cells may com-
pensate for the absence of CD4+ T cells and control secondary
Brucella infection. Similarly, a reduced IFN-g–mediated response
can be compensated for by an IL-17A–mediated response. The
precise effector mechanisms implicated in these responses remain to
be clarified, but our work opens up new areas for future investiga-
tions. These findings could improve our ability to develop protective
vaccines or therapeutic treatments against brucellosis or other in-
fectious diseases caused by intracellular bacteria. Because cellular
immunity only develops following the administration of live bac-
teria (17), live attenuated vaccines or inactivated, yet metabolically
active, bacteria seem to remain the easiest and most potent tools for
the production of candidate protective vaccines against brucellosis.
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